Background: Direct-acting antiviral (DAA) therapy has transformed the outcomes of liver transplant (LT) with hepatitis C virus (HCV). This study aimed to analyze the effects of DAA treatment for HCV-associated hepatocellular carcinoma (HCC) in LT.
Methods: We included patients confirmed with HCC on explant, analyzed data from United Network for Organ Sharing, and defined the pre-DAA era (2012-2013) and DAA era (2014-2016).
Results: HCV-associated HCC cases totaled 4778 (62%) during the study period. In the DAA era, the median recipient age was older and the median days on the waiting list were longer. For the donor, median age, body mass index, and the rate of HCV significantly increased in the DAA era. In pathology, the median largest tumor size was significantly higher; however, the rate of completed tumor necrosis was significant higher in the DAA era. The 3-year graft/patient survival had significantly improved in the DAA era. In multivariable analysis, the DAA era (hazard ratio, 0.79; 95% confidence interval, 0.68-0.91) had significantly affected the 3-year graft survival.
Conclusions: DAA has a significant beneficial effect on LT. In the DAA era, graft survival for HCV-associated HCC has been significantly improving.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.transproceed.2022.03.070 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The evolving scenario of hcv-related mixed cryoglobulinemia and B-cell lymphoma in the era of direct-acting antivirals.
Expert Rev Anti Infect Ther
January 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Introduction: Hepatitis C virus (HCV) infection represents a significant global health burden, particularly due to its extrahepatic immune-mediated manifestations, such as mixed cryoglobulinemia, associated vasculitis (CryoVas), and non-Hodgkin B-cell lymphoma (B-NHL), which pose significant challenges. The advent of direct-acting antiviral (DAA) has changed the therapeutic landscape for HCV-related complications.
Areas Covered: This review explores the evolving epidemiology and management of HCV extrahepatic manifestation and lymphoproliferative disorders in the era of DAAs.
Acute Hepatitis C: Current Status and Future Perspectives.
Viruses
November 2024
Department of Medical and Surgical Sciences, Section of Infectious Diseases, University of Foggia, 71122 Foggia, Italy.
Article Synopsis
- Hepatitis C virus (HCV) is a major public health issue, causing serious liver problems and leading to high mortality rates; the WHO aims to eliminate HCV as a public health threat by 2030.
- A significant number (50-70%) of newly infected individuals may develop chronic hepatitis C, emphasizing the need for early diagnosis and treatment to prevent complications and transmission.
- Early treatment of HCV is important, and recent analyses suggest it can be cost-effective, making it essential to focus on existing knowledge, risk factors, management strategies, and future directions in HCV treatment.
Outcomes of liver transplantation with donors older than 80 years in HCV patients treated with direct-action antivirals vs. non-HCV patients.
Med Clin (Barc)
November 2024
Department of Surgery, Faculty of Medicine, Complutense University, Madrid, Spain.
Background: Multiple studies have shown good results with the use of octogenarian donors in non-HCV recipients and its use is universally accepted worldwide. There are no studies analyzing differences between hepatitis C virus (HCV) and non-HCV recipients transplanted with donors≥80 years in the direct-action antivirals (DAA) period. The rate of liver transplantation (LT) using old donors is still low, and a change in the acceptance of these grafts could increase the liver pool available for LT.
View Article and Find Full Text PDFImpact of Sustained Virological Response on Long-Term Outcomes After Curative Resection in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma in the Era of Direct-Acting Antiviral Therapy.
Ann Surg Oncol
November 2024
Division of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Article Synopsis
- The study investigated the long-term outcomes of patients with hepatitis C virus (HCV)-related liver cancer (HCC) who underwent surgery, focusing on those who achieved sustained virologic response (SVR) from antiviral therapy versus those who didn't.
- A total of 216 patients were analyzed, revealing that those with pre- or post-SVR had better liver health and significantly improved overall survival (OS) and recurrence-free survival (RFS) compared to the non-SVR group.
- Results suggested that achieving SVR, particularly through direct-acting antiviral (DAA) therapy, was strongly linked to lower recurrence rates and increased survival rates after surgical resection of HCC.
Non-acquired immunodeficiency syndrome defining malignancies in people living with haemophilia and human immunodeficiency virus after direct-acting antiviral era.
Glob Health Med
October 2024
Division of Infectious Diseases, Advanced Clinical Research Centre, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Article Synopsis
- The study investigates non-acquired immunodeficiency syndrome-defining malignancies (NADMs) among people living with hemophilia and HIV in Japan, focusing on the period after the approval of direct-acting antivirals for hepatitis C virus (HCV).
- A nationwide survey was conducted across 395 HIV treatment facilities, collecting data on 328 individuals from 2015 to 2022, which revealed that liver cancer was the most common NADM, accounting for 43% of cases identified.
- The findings indicate a significantly higher rate of liver cancer and other malignancies in this population, particularly in younger patients, emphasizing the importance of regular cancer screening and preventive strategies for PLWH
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!